LAVAL,
QC, May 23, 2022 /PRNewswire/ -- Acasti
Pharma Inc. (Nasdaq: ACST and TSX-V: ACST) ("Acasti"; the
"Company"), a late-stage specialty pharmaceutical company with drug
delivery technologies and drug candidates addressing rare and
orphan diseases, has retained one of the industry's leading
investor relations firms, Lytham Partners, LLC, to lead a strategic
investor relations and shareholder communication program.
For more than 20 years, Lytham Partners has created a highly
diverse network of institutional investors, while creating a
framework of best practices in all aspects of corporate and
shareholder communications. In addition to their relationships with
many of the industry's most respected institutional investors,
Lytham Partners has spent the past two decades creating an
integrated platform enabling far-reaching exposure to investors in
a consistent and in-depth format including the Lytham Partners
Investor Conference Series. This platform includes a communications
and positioning approach that is streamlined via press releases,
conference calls, investor presentations, corporate profiles,
corporate access, and websites.
Jan D'Alvise, Acasti's CEO, commented, "Over the last 12 months,
Acasti has made great strides advancing our three primary drug
candidates, including last week's announcement that our lead drug
candidate, GTX-104 for the treatment of Subarachnoid Hemorrhage
(SAH), met all its planned study endpoints. We are now working with
our clinical/regulatory advisors to finalize our proposed study
design and protocol for the Phase 3 Safety Study of GTX-104. The
safety study is expected to be the final step required to seek
regulatory approval under the 505(b)(2) regulatory pathway before
submitting a New Drug Application to the FDA."
D'Alvise expanded, "Given the progress we have made, we believe
the time is appropriate to expand our visibility throughout the
institutional investment community. Lytham Partners has an
impressive track record working with companies at our stage of
development to underscore our messaging, expand our investor base,
and enact best practices to our investor communications
program."
Robert Blum, Co-Founder and
Managing Partner of Lytham Partners, LLC, said, "Jan and the team
at Acasti Pharma have done an exceptional job of moving three
assets through the clinic with a number of potential near-term
value creation points on the horizon. We look forward to
introducing the Company to our platform of investors, while
instituting best practices within their communications program, and
keeping shareholders apprised of the developments taking place at
the company."
Acasti will be participating in the Lytham Partners Summer 2022
Investor Conference being held virtually on June 21-22. Please visit
www.lythampartners.com/virtual for additional information on
meeting opportunities and presentations.
The investor relations services agreement with Lytham Partners
(the "Agreement") is for an indeterminate term and may be
terminated by Acasti Pharma at any time upon 30 days' notice. Under
the terms of the Agreement, Lytham Partners will receive a monthly
fee of US$9,500 and eligible expenses
will be reimbursed. The Agreement is subject to the approval of the
TSXV Venture Exchange.
To sign up for alerts on Acasti Pharma, please email or call
Robert Blum at
ACST@lythampartners.com or 602-889-9700.
About Acasti
Acasti Pharma Inc. (Nasdaq: ACST and
TSX-V: ACST) is a late-stage specialty pharmaceutical company
with drug delivery technologies and drug candidates addressing rare
and orphan diseases. Acasti's novel drug delivery technologies have
the potential to improve the performance of currently marketed
drugs by achieving faster onset of action, enhanced efficacy,
reduced side effects, and more convenient drug delivery—all which
could help to increase treatment compliance and improve patient
outcomes.
Acasti's three lead clinical assets have each been granted
Orphan Drug Designation by the FDA, which provide the assets with
seven years of marketing exclusivity post-launch in the United States, and additional intellectual
property protection with over 40 granted and pending patents.
Acasti's lead clinical assets target underserved orphan
diseases:
(i) GTX-104, an intravenous infusion
targeting Subarachnoid Hemorrhage (SAH), a rare and
life-threatening medical emergency in which bleeding occurs over
the surface of the brain in the subarachnoid space between the
brain and skull;
(ii) (ii) GTX-102, an oral mucosal spray
targeting Ataxia-telangiectasia (A-T), a progressive,
neurodegenerative genetic disease that primarily affects children,
causing severe disability, and for which no treatment currently
exists; and
(iii) (iii) GTX-101, a topical spray,
targeting Postherpetic Neuralgia (PHN), a persistent and often
debilitating neuropathic pain caused by nerve damage from the
varicella zoster virus (shingles), which may persist for months and
even years.
For more information, please visit:
https://www.acastipharma.com/en.
About Forward-Looking Statements
This press release
contains forward-looking statements. Forward-looking statements
include, but are not limited to, statements that express the
Company's intentions, beliefs, expectations, strategies,
predictions or any other statements related to the Company's future
activities or future events
or conditions. These statements are based on current
expectations, estimates and projections about the Company's
business based, in part, on assumptions made by the Company's
management. These statements are not guarantees of future
performances and involve risks, uncertainties and assumptions that
are difficult to predict. Therefore, actual outcomes and results
may differ materially from what is expressed or forecasted in the
forward-looking statements due to numerous factors, including those
risks discussed in the Company's annual report on Form 10-K and in
other documents that we file from time to time with the SEC. Any
forward-looking statements speak only as of the date on which they
are made, and the Company does not undertake any obligation to
update any forward-looking statement to reflect events or
circumstances after the date of this report, except as required by
law.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/acasti-pharma-inc-retains-lytham-partners-to-lead-strategic-investor-relations-and-shareholder-communication-program-301553139.html
SOURCE Acasti Pharma Inc.